Clinical trials
Enterobacteriaceae Infections clinical trials
Below are recruiting enterobacteriaceae infections clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03671967RecruitingPhase 4
Compare two antibiotics for hard-to-treat E. coli and Klebsiella bloodstream infections
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
Calgary, AlbertaAges 18 years+ - NCT06051513Recruiting
Testing colistimethate for CRE infection in hospitalized patients
This trial tests a medicine called colistimethate sodium for people in the hospital with a serious infection (pneumonia or bloodstream infection) caused by a resistant bacteria called CRE. The goal is to see if this antibiotic can effectively treat the infection.
Hefei, AnhuiAges 18–85 - NCT04535661Recruiting
Study of who develops carbapenem-resistant infections in PICU children
This study looks at factors that make some hospitalized children in the pediatric intensive care unit (PICU) develop or carry germs called carbapenem-resistant Enterobacteriaceae. It aims to understand who is at higher risk and why, which may help prevent infections in the future.
Shanghai, Shanghai MunicipalityAges 4 weeks–18 years - NCT04759001RecruitingPhase 1/Phase 2
Fecal treatment to clear gut bacteria resistant to antibiotics
This study tests a stool-based treatment (fecal microbiota treatment) to help remove “carbapenem-resistant” bacteria living in the gut. If you carry these bacteria without being sick, the goal is to reduce or stop that colonization.
RomeAges 18–90 - NCT05791396RecruitingPhase 1/Phase 2
Fecal microbiome therapy to clear hard-to-treat gut germs
This trial looks at a treatment made from stool donors (called fecal microbiome therapy) to help remove carbapenem-resistant gut bacteria in the body. It’s mainly for adults who recently tested positive for these bacteria on a rectal swab, and it checks whether the therapy can help eradicate the germs.
RomaAges 18–85 - NCT05979545RecruitingPhase 4
Early treatment with ceftazidime-avibactam for serious infections
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
Kuala LumpurAges Any age - NCT05871476Recruiting
Study to reduce resistant bacteria spread in young children
This study tests ways to reduce how a hard-to-treat bacterial germ spreads between hospitals, homes, communities, and animals. It focuses on children under 2 years old in the selected hospital area because they may be more likely to pick up and spread the bacteria.
Thái Bình, Thai BinhAges Up to 2 years - NCT06258551Recruiting
Tracking hard-to-treat bacteria in ICU and transplant patients
This study will track how certain hard-to-treat bacteria spread and cause infections in people who are in the intensive care unit (ICU) or have had a stem cell transplant. The goal is to better understand and prevent these infections in vulnerable patients.
Houston, TexasAges 18 years+ - NCT04014413Recruiting
Fecal transplant for gut and immune-related conditions
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
Hong Kong, ShatinAges Any age - NCT03465683Recruiting
Study of germ carriage that produces ESBL enzymes
This study looks at whether certain bacteria that carry ESBL enzymes are spreading between people. To join, you would need lab-confirmed evidence that you carry these bacteria based on routine samples taken during usual care.
BaselAges 1 year+ - NCT07345923Recruiting
Rectal swab test to predict resistant infections in ICU
This study looks at whether a simple rectal swab test can help predict the risk of developing infections that are resistant to common antibiotics. It focuses on patients in the intensive care unit (ICU) who have already had this swab done as part of their care.
StrasbourgAges 18 years+ - NCT07039955Enrolling by invitation
Preventing CPE germ spread in ICU patients
This trial tests whether daily cleansing with a special soap (chlorhexidine) combined with thoughtful use of antibiotics and stomach acid reducers can help prevent the spread of a tough germ called CPE (carbapenemase-producing Enterobacteriaceae) in the ICU. It aims to keep ICU patients safer from infection.
Chuncheon, Gangwon-doAges 19 years+ - NCT07089186RecruitingPhase 3
Study of meropenem and pralurbactam for certain antibiotic-resistant infections
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
ShanghaiAges 18–80 - NCT05035342RecruitingPhase 3
Fecal transplant to clear resistant gut bacteria
This Phase 3 study tests whether a fecal microbiota transplant (FMT) can eliminate hard-to-treat bacteria in the gut, such as ESBL or carbapenem-resistant bacteria. If it works, it may reduce future infections and antibiotic-resistant illness.
ClichyAges 18–105 - NCT07086391Recruiting
Inhaled Polymyxin B for Resistant Pneumonia
This trial tests different ways of giving an inhaled antibiotic (polymyxin B) to people on a ventilator who have pneumonia caused by tough bacteria that don't respond to usual antibiotics. The goal is to find the best way to deliver the medicine to help clear the infection.
Fuzhou, FujianAges 18–90 - NCT06636890Enrolling by invitation
Testing a new method for detecting certain bacteria in lung infections
This study checks if a special test (Xpert Carba-R) can find a type of drug-resistant bacteria, called CRE, in fluid from the lungs and in rectal swabs. It might help doctors treat lower respiratory tract infections more effectively.
Nanjing, JiangsuAges 18–90 - NCT05475574Recruiting
Stopping extra cleaning for some resistant bacteria in geriatrics
This trial looks at whether stopping extra “contact precautions” (special measures to prevent spread) is safe for older hospital patients who carry a certain type of hard-to-treat gut bacteria. It may reduce unnecessary isolation and improve comfort, while still aiming to prevent infections.
MetzAges 65 years+ - NCT05565222RecruitingPhase 3
Testing two antibiotics as alternatives for ICU severe ESBL infections
This study compares two antibiotics—piperacillin-tazobactam or temocillin—to treat severe ICU infections caused by certain hard-to-treat gut bacteria (ESBL). It may help patients avoid the use of carbapenem antibiotics like meropenem when the bacteria are susceptible.
ParisAges 18 years+
Hear when a new Enterobacteriaceae Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for enterobacteriaceae infections?
- Yes. Clin2 currently lists 18 recruiting enterobacteriaceae infections studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a enterobacteriaceae infections trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a enterobacteriaceae infections trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.